Intensive Care Resources and 60-Day Survival of Critically-Ill COVID-19 Patients.
60-day survival
ards
covid-19
icu resources
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
07 Feb 2021
07 Feb 2021
Historique:
entrez:
17
3
2021
pubmed:
18
3
2021
medline:
18
3
2021
Statut:
epublish
Résumé
Germany reported sufficient intensive care unit (ICU) resources throughout the first wave of coronavirus disease 2019 (COVID-19). The treatment of critically ill COVID-19 patients without rationing may improve the outcome. We therefore analyzed ICU resources allocated to COVID-19 patients with respiratory failure and their outcomes. Retrospectively, we enrolled severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) polymerase chain reaction (PCR)-positive patients with respiratory failure from 03/08/2020 to 04/08/2020 and followed until 05/28/2020 in the university hospital of Freiburg, Germany. In the defined interval, 34 COVID-19 patients were admitted to the ICU with median age of 67±13 (31-86) years. Six of 34 (17.6%) were female. All patients suffered from moderate or severe acute respiratory distress syndrome (ARDS), 91.2% of the patients were intubated and 23.5% required extracorporeal membrane oxygenation (ECMO). Proning was performed in 67.6%, renal replacement therapy (RRT) was required in 35.3%. Ninety-six percent required more than 20 nursing hours per day. Mean ICU stay was 21±19 (1-81) days. Sixty-day survival of critically ill COVID-19 patients was 50.0% (17/34). Causes of death were multi-organ failure (52.9%), refractory ARDS (17.6%) and intracerebral hemorrhage (17.6%). Treatment of critically ill COVID-19 patients is protracted and resource-intense. In a context without resources shortage, 50% of COVID-19 with respiratory failure survived up to 60 days.
Sections du résumé
BACKGROUND
BACKGROUND
Germany reported sufficient intensive care unit (ICU) resources throughout the first wave of coronavirus disease 2019 (COVID-19). The treatment of critically ill COVID-19 patients without rationing may improve the outcome. We therefore analyzed ICU resources allocated to COVID-19 patients with respiratory failure and their outcomes.
METHODS
METHODS
Retrospectively, we enrolled severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) polymerase chain reaction (PCR)-positive patients with respiratory failure from 03/08/2020 to 04/08/2020 and followed until 05/28/2020 in the university hospital of Freiburg, Germany.
RESULTS
RESULTS
In the defined interval, 34 COVID-19 patients were admitted to the ICU with median age of 67±13 (31-86) years. Six of 34 (17.6%) were female. All patients suffered from moderate or severe acute respiratory distress syndrome (ARDS), 91.2% of the patients were intubated and 23.5% required extracorporeal membrane oxygenation (ECMO). Proning was performed in 67.6%, renal replacement therapy (RRT) was required in 35.3%. Ninety-six percent required more than 20 nursing hours per day. Mean ICU stay was 21±19 (1-81) days. Sixty-day survival of critically ill COVID-19 patients was 50.0% (17/34). Causes of death were multi-organ failure (52.9%), refractory ARDS (17.6%) and intracerebral hemorrhage (17.6%).
CONCLUSIONS
CONCLUSIONS
Treatment of critically ill COVID-19 patients is protracted and resource-intense. In a context without resources shortage, 50% of COVID-19 with respiratory failure survived up to 60 days.
Identifiants
pubmed: 33728167
doi: 10.7759/cureus.13210
pmc: PMC7946605
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e13210Informations de copyright
Copyright © 2021, Lang et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
Intensive Care Med. 2020 May;46(5):854-887
pubmed: 32222812
Crit Care. 2017 May 30;21(1):122
pubmed: 28554331
Respir Care. 2017 Jan;62(1):113-122
pubmed: 27803355
CMAJ. 2005 Aug 30;173(5):489-95
pubmed: 16129869
Lancet Respir Med. 2021 Jan 12;:
pubmed: 33450202
JAMA. 2012 Jun 20;307(23):2526-33
pubmed: 22797452
N Engl J Med. 2020 May 21;382(21):2012-2022
pubmed: 32227758
Lancet Respir Med. 2020 May;8(5):475-481
pubmed: 32105632
Nephrol Dial Transplant. 2013 Dec;28(12):2940-5
pubmed: 24121762
JAMA. 2020 May 26;323(20):2052-2059
pubmed: 32320003
Pneumologie. 2020 Jun;74(6):337-357
pubmed: 32323287
Dtsch Arztebl Int. 2020 Apr 17;117(16):271-278
pubmed: 32519944
JAMA. 2020 Apr 28;323(16):1612-1614
pubmed: 32191259
Crit Care. 2013 Feb 04;17(1):204
pubmed: 23394211
Neurocrit Care. 2021 Feb 23;:
pubmed: 33619668
J Med Virol. 2020 Nov;92(11):2511-2515
pubmed: 32293741
Ann Intern Med. 2020 Aug 18;173(4):268-277
pubmed: 32374815
PLoS One. 2020 Nov 12;15(11):e0242127
pubmed: 33180830
Thromb Res. 2020 Jul;191:145-147
pubmed: 32291094